HDAC6 and Miyoshi myopathy: In this study, we evaluated the anticancer activity of a combination of the specific HDAC6 inhibitor MPT0G413 and BTZ in both in vitro and in vivo models and studied the effects of this combination therapy on parameters such as cytokine secretion and cell adhesion in a microenvironment comprising MM cells and BM.